• Something wrong with this record ?

aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model

J. Chen, Q. Ma, JS. King, Y. Sun, B. Xu, X. Zhang, S. Zohrabian, H. Guo, W. Cai, G. Li, I. Bruno, JP. Cooke, C. Wang, M. Kontaridis, DZ. Wang, H. Luo, WT. Pu, Z. Lin

. 2020 ; 3 (1) : . [pub] 20191216

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21013010

Grant support
R01 HL146134 NHLBI NIH HHS - United States
R01 HL093242 NHLBI NIH HHS - United States
R01 HL116461 NHLBI NIH HHS - United States
R01 HL149401 NHLBI NIH HHS - United States
R56 HL138454 NHLBI NIH HHS - United States
R01 HL141853 NHLBI NIH HHS - United States

Myocardial recovery from ischemia-reperfusion (IR) is shaped by the interaction of many signaling pathways and tissue repair processes, including the innate immune response. We and others previously showed that sustained expression of the transcriptional co-activator yes-associated protein (YAP) improves survival and myocardial outcome after myocardial infarction. Here, we asked whether transient YAP expression would improve myocardial outcome after IR injury. After IR, we transiently activated YAP in the myocardium with modified mRNA encoding a constitutively active form of YAP (aYAP modRNA). Histological studies 2 d after IR showed that aYAP modRNA reduced cardiomyocyte (CM) necrosis and neutrophil infiltration. 4 wk after IR, aYAP modRNA-treated mice had better heart function as well as reduced scar size and hypertrophic remodeling. In cultured neonatal and adult CMs, YAP attenuated H2O2- or LPS-induced CM necrosis. TLR signaling pathway components important for innate immune responses were suppressed by YAP/TEAD1. In summary, our findings demonstrate that aYAP modRNA treatment reduces CM necrosis, cardiac inflammation, and hypertrophic remodeling after IR stress.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21013010
003      
CZ-PrNML
005      
20210716110613.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.26508/lsa.201900424 $2 doi
035    __
$a (PubMed)31843959
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chen, Jinmiao $u Boston Children's Hospital, Boston, MA, USA ; Department of Cardiovascular Surgery and Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China
245    10
$a aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model / $c J. Chen, Q. Ma, JS. King, Y. Sun, B. Xu, X. Zhang, S. Zohrabian, H. Guo, W. Cai, G. Li, I. Bruno, JP. Cooke, C. Wang, M. Kontaridis, DZ. Wang, H. Luo, WT. Pu, Z. Lin
520    9_
$a Myocardial recovery from ischemia-reperfusion (IR) is shaped by the interaction of many signaling pathways and tissue repair processes, including the innate immune response. We and others previously showed that sustained expression of the transcriptional co-activator yes-associated protein (YAP) improves survival and myocardial outcome after myocardial infarction. Here, we asked whether transient YAP expression would improve myocardial outcome after IR injury. After IR, we transiently activated YAP in the myocardium with modified mRNA encoding a constitutively active form of YAP (aYAP modRNA). Histological studies 2 d after IR showed that aYAP modRNA reduced cardiomyocyte (CM) necrosis and neutrophil infiltration. 4 wk after IR, aYAP modRNA-treated mice had better heart function as well as reduced scar size and hypertrophic remodeling. In cultured neonatal and adult CMs, YAP attenuated H2O2- or LPS-induced CM necrosis. TLR signaling pathway components important for innate immune responses were suppressed by YAP/TEAD1. In summary, our findings demonstrate that aYAP modRNA treatment reduces CM necrosis, cardiac inflammation, and hypertrophic remodeling after IR stress.
650    _2
$a adaptorové proteiny signální transdukční $x aplikace a dávkování $x genetika $7 D048868
650    _2
$a zvířata $7 D000818
650    _2
$a novorozená zvířata $7 D000831
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a kardiomegalie $x farmakoterapie $x etiologie $7 D006332
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a kultivované buňky $7 D002478
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a lidé $7 D006801
650    _2
$a injekce intramuskulární $7 D007273
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a reperfuzní poškození myokardu $x komplikace $7 D015428
650    _2
$a myokarditida $x farmakoterapie $x etiologie $7 D009205
650    _2
$a myokard $x imunologie $7 D009206
650    _2
$a kardiomyocyty $x metabolismus $7 D032383
650    _2
$a infiltrace neutrofily $x účinky léků $7 D020556
650    _2
$a editace RNA $7 D017393
650    _2
$a messenger RNA $x aplikace a dávkování $x genetika $7 D012333
650    _2
$a transkripční faktory $x aplikace a dávkování $x genetika $7 D014157
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ma, Qing $u Boston Children's Hospital, Boston, MA, USA
700    1_
$a King, Justin S $u Boston Children's Hospital, Boston, MA, USA
700    1_
$a Sun, Yan $u Masonic Medical Research Institute, Utica, NY, USA
700    1_
$a Xu, Bing $u Masonic Medical Research Institute, Utica, NY, USA
700    1_
$a Zhang, Xiaoyu $u Boston Children's Hospital, Boston, MA, USA
700    1_
$a Zohrabian, Sylvia $u Boston Children's Hospital, Boston, MA, USA
700    1_
$a Guo, Haipeng $u Boston Children's Hospital, Boston, MA, USA ; Department of Critical Care Medicine, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan, China
700    1_
$a Cai, Wenqing $u Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA, USA
700    1_
$a Li, Gavin $u Boston Children's Hospital, Boston, MA, USA
700    1_
$a Bruno, Ivone $u Houston Methodist Research Institute, Houston, TX, USA
700    1_
$a Cooke, John P $u Houston Methodist Research Institute, Houston, TX, USA
700    1_
$a Wang, Chunsheng $u Department of Cardiovascular Surgery and Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China
700    1_
$a Kontaridis, Maria $u Masonic Medical Research Institute, Utica, NY, USA
700    1_
$a Wang, Da-Zhi $u Boston Children's Hospital, Boston, MA, USA
700    1_
$a Luo, Hongbo $u Boston Children's Hospital, Boston, MA, USA
700    1_
$a Pu, William T $u Boston Children's Hospital, Boston, MA, USA wpu@pulab.org ; Harvard Stem Cell Institute, Cambridge, MA, USA
700    1_
$a Lin, Zhiqiang $u Boston Children's Hospital, Boston, MA, USA zlin@mmri.edu ; Masonic Medical Research Institute, Utica, NY, USA
773    0_
$w MED00197314 $t Life science alliance $x 2575-1077 $g Roč. 3, č. 1 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31843959 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210716110613 $b ABA008
999    __
$a ok $b bmc $g 1651239 $s 1133389
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 3 $c 1 $e 20191216 $i 2575-1077 $m Life science alliance $n Life sci. alliance $x MED00197314
GRA    __
$a R01 HL146134 $p NHLBI NIH HHS $2 United States
GRA    __
$a R01 HL093242 $p NHLBI NIH HHS $2 United States
GRA    __
$a R01 HL116461 $p NHLBI NIH HHS $2 United States
GRA    __
$a R01 HL149401 $p NHLBI NIH HHS $2 United States
GRA    __
$a R56 HL138454 $p NHLBI NIH HHS $2 United States
GRA    __
$a R01 HL141853 $p NHLBI NIH HHS $2 United States
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options